EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates

Seyed Farzad Baniahmad, Alina Burlacu, Laurence Delafosse, Mauro Acchione, Miriam Simmons, Binbing Ling, Umar Iqbal, Maria J Moreno, Gregory De Crescenzo iD, Yves Durocher iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Seyed Farzad Baniahmad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, Montréal, H3C 3J7 Québec, Canada. Hauptthemen laut MEDLINE: Immunoconjugates, Peptides, Trastuzumab. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates are revolutionizing cancer treatment. However, their manufacturing still requires improvements in conjugation technology, especially for the control of the drug-to-antibody ratio (DAR). Here, we investigate the use of the de novo designed coiled-coil heterodimer, composed of the Ecoil and Kcoil peptides, as a new strategy for generating antibody conjugates with high homogeneity and a controllable DAR. More precisely, we investigated the assembly, stability, and tumor targeting of two conjugated antibodies made of (1) trastuzumab with C-terminal Ecoils (TZM-Ecoil) noncovalently paired with Kcoil peptides fused to the monomeric red fluorescent protein (Kcoil-mRFP), yielding TZM-E/K-mRFP or (2) TZM-Ecoil noncovalently paired to Kcoil peptide covalently linked to the fluorescent dye CF750 (Kcoil-CF750), yielding TZM-E/K-CF750. Results from the in vitro stability assessment of these complexes in blood serum revealed that their integrity was maintained. Furthermore, in vivo biodistribution and tumor localization data using a HER2-expressing SKOV3 xenograft mouse model indicated efficient tumor targeting and retention for up to 10 days postinjection of the TZM-E/K-CF750 conjugate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesPeptidesTrastuzumabHumansAnimalsMiceCell Line, TumorFemaleTissue DistributionRed Fluorescent ProteinMice, Nude

Substanzen

ImmunoconjugatesPeptidesTrastuzumabRed Fluorescent Protein

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Université de Montréal, Montréal, H3C 3J7 Québec, Canada.
  • Human Health Therapeutics Research Centre, Building Montreal-Royalmount, National Research Council Canada, Montréal, H4P 2R2 Québec, Canada.
  • PROTEO: The Quebec Network for Research on Protein Function, Structure, and Engineering, Université du Québec a Montréal, Montréal, H3C 3P8 Québec, Canada.
  • Human Health Therapeutics Research Center, National Research Council Canada, Ottawa, K1A 0R6 Ontario, Canada.
  • Department of Chemical Engineering, Polytechnique Montréal, Montréal, H3C 3A7 Québec, Canada.

ORCID-Profile: Gregory De Crescenzo, Yves Durocher

Förderung

  • Natural Sciences and Engineering Research Council of Canada

Zitieren

APA

Baniahmad, S. F., Burlacu, A., Delafosse, L., Acchione, M., Simmons, M., Ling, B., Iqbal, U., Moreno, M. J., De Crescenzo, G., & Durocher, Y. (2025). Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00178

Vancouver

Baniahmad SF, Burlacu A, Delafosse L, Acchione M, Simmons M, Ling B, et al. Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00178

BibTeX
@article{Baniahmad2025,
  author = {Baniahmad, Seyed Farzad and Burlacu, Alina and Delafosse, Laurence and Acchione, Mauro and Simmons, Miriam and Ling, Binbing and Iqbal, Umar and Moreno, Maria J and De Crescenzo, Gregory and Durocher, Yves},
  title = {Use of Coiled-Coil Affinity Peptides to Manufacture Antibody Conjugates},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00178}
}
Kostenlos starten →